| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
|
|---|
| Research Abstract |
We assessed the antiarthrogenic and the antifibrotic effects ofdepletion of FRbeta-expressing macrophages in methylated BSA induced arthritis and bleomycin induced skin fibrosis models using a recombinant immunotoxin to FRbeta, respectively. Skin fibrosis was evaluated by the change of skin thickness and hydroxyproline content on Day 29. The TGFbeta1 mRNA levels in the treated skin were assessed by quantitative real-time RT-PCR on Day 9. Anti-FRbeta-PE38 treatment led to a dramatic reduction in the number of FRbeta-expressing macrophages. Additionally, skin thickness and hydroxyproline content, were markedly reduced. TGFbeta1 mRNA levels were also down-regulated after the treatment. TGFbeta1 expression was enriched in FRbeta-expressing macrophages compared with FRbeta-negative macrophages. Anti-FRbeta-PE38 treatment efficiently depleted FRbeta-expressing macrophages and consequently alleviated BLM-induced skin fibrosis.
|
